Associate Professor, Department of Medicine, Institute of Medical Sciences, BHU, Varanasi, India
*Corresponding author Dr. Anup Singh Associate Professor, Medicine, IMS, BHU, Varanasi-221005, India, E-mail: dranupbhu@gmail.com
Online published on 7 February, 2017.
The sparse treatment options in Visceral Leishmaniasis (VL) makes its treatment very challenging. Long treatment duration and toxic adverse effect of anti-lesihmanial drugs further add to the problem of effective management. As still no effective vaccine is available, the sole treatment of VL is only based on anti-lesihmanial drugs. Also the increasing resistance to existing drugs also pose a hurdle to VL treatment. In Indian sub-continent, single dose of liposomal amphotericin B (L-AmB) and multidrug therapy (L-AmB + miltefosine, L-AmB + paromomycin (PM), or miltefosine + PM) are the treatment of choice for VL.
Visceral Leishmaniasis (VL), liposomal amphotericin
